Details of the Drug

General Information of Drug (ID: DM98IXF)

Drug Name

Triamcinolone

Synonyms

Adcortyl; Aristocort; Celeste; Cinolone; Delphicort; Fluoxiprednisolone; Fluoxyprednisolone; Fougera; Ione; Kenacort; Ledercort; Mycolog; Omcilon; Omicilon; Orion; Rodinolone; Tiamcinolonum; Triamcet; Triamcinalone; Triamcinlon; Triamcinolon; Triamcinolona; Triamcinolonum; Tricortale; Trilone; Tristoject; Volon; Aristocort Tablets; Triamcinolonum [INN]; CL 19823; Aristocort (TN); Azmacort (TN); Cinolone-T; Fougera (TN); Kenacort (TN); Kenacort-AG; Kenalog (TN); Nasacort (TN); SK-Triamcinolone; Tiamcinolonum [INN-Latin]; Triam-Tablinen; Triamcinolona [INN-Spanish]; Tricortone (TN); Triderm (TN); Triesence (TN); Trilone (TN); Tristoject (TN); Volon A (TN); Tri-Nasal (TN); Triamcinolone (JP15/USP/INN); Triamcinolone [USAN:INN:BAN:JAN]; Droxypregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dio; TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7)); Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy-(8CI); Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha); (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione; 11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-16-alpha-hydroxyprednisolone; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d; 9.Alpha.-Fluoro-16.alpha.-hydroxyprednisolone; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9alpha-Fluoro-16alpha-hydroxyprednisolone

Indication

Disease Entry	ICD 11	Status	REF
Acute adrenal insufficiency	N.A.	Approved	[1]
Addison disease	5A74.0	Approved	[1]
Allergic rhinitis	CA08.0	Approved	[2]
Alopecia areata	ED70.2	Approved	[1]
Angioedema	4A00.15	Approved	[1]
Aspiration pneumonitis	N.A.	Approved	[1]
Autoimmune haemolytic anaemia	3A20	Approved	[1]
Bacterial infection	1A00-1C4Z	Approved	[1]
Bursitis	N.A.	Approved	[1]
Cerebral edema	8D60.1	Approved	[1]
Congenital adrenal hyperplasia	5A71.01	Approved	[1]
Crohn disease	DD70	Approved	[1]
Cutaneous candidiasis	1F23.14	Approved	[1]
Dermatitis herpetiformis	EB44	Approved	[1]
Diamond-Blackfan anemia	N.A.	Approved	[1]
Disorder of orbital region	N.A.	Approved	[1]
Epicondylitis	N.A.	Approved	[1]
Erythema multiforme	N.A.	Approved	[1]
Exanthem	N.A.	Approved	[1]
Gingival disorder	N.A.	Approved	[1]
Granuloma annulare	N.A.	Approved	[1]
Inflammation	1A00-CA43.1	Approved	[1]
Inflammatory bowel disease	DD72	Approved	[1]
Miliary tuberculosis	N.A.	Approved	[1]
Multiple sclerosis	8A40	Approved	[1]
Mycosis fungoides	2B01	Approved	[1]
Primary cutaneous T-cell lymphoma	N.A.	Approved	[1]
Psoriasis	EA90	Approved	[1]
Psoriatic arthritis	FA21	Approved	[1]
Rheumatic heart disease	N.A.	Approved	[1]
Sarcoidosis	4B20.5	Approved	[1]
Seasonal allergic rhinitis	CA08.01	Approved	[1]
Serum sickness	N.A.	Approved	[1]
Severe asthma	CA23	Approved	[1]
Skin disease	EA00-EM0Z	Approved	[1]
Subacute bursitis	N.A.	Approved	[1]
Sympathetic ophthalmia	N.A.	Approved	[1]
Systemic lupus erythematosus	4A40.0	Approved	[1]
Acquired thrombocytopenia	N.A.	Investigative	[1]
Asthma	CA23	Investigative	[1]
Beta-thalassemia major	N.A.	Investigative	[1]
Classic Hodgkin lymphoma	N.A.	Investigative	[1]
Follicular lymphoma	2A80	Investigative	[1]
Keloid	EE60	Investigative	[1]
Rheumatoid arthritis	FA20	Investigative	[1]
Synovitis	N.A.	Investigative	[1]
Trichinellosis	N.A.	Investigative	[1]
Uveitis	9A96.Z	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Antiinflammatory Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

394.4

Logarithm of the Partition Coefficient (xlogp)

1.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 36.0 +/- 6.2 mcgh/L [3]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 5.23 +/- 0.84 mcg/L [3]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2.24 +/- 0.78 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Clearance: The total body clearance of drug is 0.57 L/h [3]
Elimination: Approximately 20% of a dose of triamcinolone is recovered in the urine as the unchanged drug, 25% is recovered as 6-beta-hydroxy-triamcinolone, and 5% is recovered as unidentified metabolites [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 2.7 hours [3]
Vd: The volume of distribution (Vd) of drug is 115.2 +/- 10 L [3]
Water Solubility: The ability of drug to dissolve in water is measured as 0.08 mg/mL [4]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Malignant melanoma	Not Available	TF	OT41PEMS	[6]
Malignant melanoma	Not Available	INS	OTZ85PDU	[6]
-----------

Chemical Identifiers

Formula: C21H27FO6
IUPAC Name: (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
Canonical SMILES: C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@H]([C@@]2(C(=O)CO)O)O)CCC4=CC(=O)C=C[C@@]43C)F)O
InChI: InChI=1S/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13-,14-,15+,16-,18-,19-,20-,21-/m0/s1
InChIKey: GFNANZIMVAIWHM-OBYCQNJPSA-N

Cross-matching ID

PubChem CID: 31307
ChEBI ID: CHEBI:9667
CAS Number: 124-94-7
DrugBank ID: DB00620
TTD ID: D03BLF
ACDINA ID: D01501

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glucocorticoid receptor (NR3C1)	TTYRL6O	GCR_HUMAN	Modulator	[7]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
C-C motif chemokine 2 (CCL2)	OTAD2HEL	CCL2_HUMAN	Gene/Protein Processing	[8]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Gene/Protein Processing	[9]
Glucocorticoid receptor (NR3C1)	OTCI2YDI	GCR_HUMAN	Gene/Protein Processing	[10]
Insulin (INS)	OTZ85PDU	INS_HUMAN	Drug Response	[6]
Mineralocorticoid receptor (NR3C2)	OT0F2V2Z	MCR_HUMAN	Gene/Protein Processing	[10]
Pro-opiomelanocortin (POMC)	OTV41F7T	COLI_HUMAN	Protein Interaction/Cellular Processes	[11]
Serotransferrin (TF)	OT41PEMS	TRFE_HUMAN	Drug Response	[6]
Vascular endothelial growth factor A, long form	OTIM9MZ3	VEGFA_HUMAN	Gene/Protein Processing	[8]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Triamcinolone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Minor	Decreased absorption of Triamcinolone due to altered gastric pH caused by Sodium bicarbonate.	Acidosis [5C73]	[12]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Triamcinolone caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[13]
Posaconazole	DMUL5EW	Major	Decreased metabolism of Triamcinolone caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[14]
Levalbuterol	DM5YBO1	Minor	Increased risk of hypokalemia by the combination of Triamcinolone and Levalbuterol.	Asthma [CA23]	[15]
Terbutaline	DMD4381	Minor	Increased risk of hypokalemia by the combination of Triamcinolone and Terbutaline.	Asthma [CA23]	[14]
Pirbuterol	DMI5678	Minor	Increased risk of hypokalemia by the combination of Triamcinolone and Pirbuterol.	Asthma [CA23]	[14]
Salbutamol	DMN9CWF	Minor	Increased risk of hypokalemia by the combination of Triamcinolone and Salbutamol.	Asthma [CA23]	[15]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Triamcinolone and Roflumilast.	Asthma [CA23]	[16]
Formoterol	DMSOURV	Minor	Increased risk of hypokalemia by the combination of Triamcinolone and Formoterol.	Asthma [CA23]	[14]
Ofloxacin	DM0VQN3	Major	Increased risk of tendinitis/tendon rupture by the combination of Triamcinolone and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[17]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Triamcinolone caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[18]
Clarithromycin	DM4M1SG	Major	Decreased metabolism of Triamcinolone caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[14]
Trovafloxacin	DM6AN32	Major	Increased risk of tendinitis/tendon rupture by the combination of Triamcinolone and Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[17]
Sparfloxacin	DMB4HCT	Major	Increased risk of tendinitis/tendon rupture by the combination of Triamcinolone and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[17]
Gemifloxacin	DMHT34O	Major	Increased risk of tendinitis/tendon rupture by the combination of Triamcinolone and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[17]
Norfloxacin	DMIZ6W2	Major	Increased risk of tendinitis/tendon rupture by the combination of Triamcinolone and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[17]
ABT-492	DMJFD2I	Major	Increased risk of tendinitis/tendon rupture by the combination of Triamcinolone and ABT-492.	Bacterial infection [1A00-1C4Z]	[17]
Levofloxacin	DMS60RB	Major	Increased risk of tendinitis/tendon rupture by the combination of Triamcinolone and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[17]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Triamcinolone caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[14]
Lomefloxacin	DMVRH9C	Major	Increased risk of tendinitis/tendon rupture by the combination of Triamcinolone and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[17]
Telithromycin	DMZ4P3A	Major	Decreased metabolism of Triamcinolone caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[14]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Triamcinolone caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[19]
Tucatinib	DMBESUA	Major	Decreased metabolism of Triamcinolone caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[14]
Vilanterol	DMF5EK1	Minor	Increased risk of hypokalemia by the combination of Triamcinolone and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[15]
Salmeterol	DMIEU69	Minor	Increased risk of hypokalemia by the combination of Triamcinolone and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[14]
Indacaterol	DMQJHR7	Minor	Increased risk of hypokalemia by the combination of Triamcinolone and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[14]
Arformoterol	DMYM974	Minor	Increased risk of hypokalemia by the combination of Triamcinolone and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[14]
Phenylbutazone	DMAYL0T	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Phenylbutazone.	Chronic pain [MG30]	[20]
Ketoprofen	DMRKXPT	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Ketoprofen.	Chronic pain [MG30]	[20]
Isoproterenol	DMK7MEY	Minor	Increased risk of hypokalemia by the combination of Triamcinolone and Isoproterenol.	Conduction disorder [BC63]	[15]
Mivacurium	DM473VD	Moderate	Additive neuromuscular blocking effects by the combination of Triamcinolone and Mivacurium.	Corneal disease [9A76-9A78]	[14]
Pancuronium	DMB0VY8	Moderate	Additive neuromuscular blocking effects by the combination of Triamcinolone and Pancuronium.	Corneal disease [9A76-9A78]	[14]
Tubocurarine	DMBZIVP	Moderate	Additive neuromuscular blocking effects by the combination of Triamcinolone and Tubocurarine.	Corneal disease [9A76-9A78]	[14]
Mifepristone	DMGZQEF	Major	Decreased metabolism of Triamcinolone caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[21]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Triamcinolone caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[22]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Triamcinolone caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[23]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Triamcinolone caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[24]
Nefazodone	DM4ZS8M	Major	Decreased metabolism of Triamcinolone caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[14]
Primidone	DM0WX6I	Moderate	Increased metabolism of Triamcinolone caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[25]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Triamcinolone caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[26]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Triamcinolone caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[27]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Triamcinolone caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[28]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Triamcinolone caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[29]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Triamcinolone caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[16]
Ethotoin	DMXWOCP	Moderate	Increased metabolism of Triamcinolone caused by Ethotoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[29]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Triamcinolone caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[25]
Mefenamic acid	DMK7HFI	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Mefenamic acid.	Female pelvic pain [GA34]	[20]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Triamcinolone caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[30]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Triamcinolone caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[14]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Triamcinolone caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[31]
Ketoconazole	DMPZI3Q	Major	Decreased metabolism of Triamcinolone caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[14]
Bumetanide	DMRV7H0	Moderate	Increased risk of hypokalemia by the combination of Triamcinolone and Bumetanide.	Heart failure [BD10-BD1Z]	[32]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Triamcinolone caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[14]
Telaprevir	DMMRV29	Major	Decreased metabolism of Triamcinolone caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[14]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Triamcinolone caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[33]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Triamcinolone caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[34]
Delavirdine	DM3NF5G	Major	Decreased metabolism of Triamcinolone caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Triamcinolone caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Triamcinolone caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Efavirenz	DMC0GSJ	Moderate	Increased metabolism of Triamcinolone caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Saquinavir	DMG814N	Major	Decreased metabolism of Triamcinolone caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Triamcinolone caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[36]
Amprenavir	DMLMXE0	Major	Decreased metabolism of Triamcinolone caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Triamcinolone caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Atazanavir	DMSYRBX	Major	Decreased metabolism of Triamcinolone caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[14]
Bempedoic acid	DM1CI9R	Major	Increased risk of tendinitis/tendon rupture by the combination of Triamcinolone and Bempedoic acid.	Hyper-lipoproteinaemia [5C80]	[37]
Teriflunomide	DMQ2FKJ	Major	Additive immunosuppressive effects by the combination of Triamcinolone and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[38]
Conivaptan	DM1V329	Major	Decreased metabolism of Triamcinolone caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[14]
Meclofenamic acid	DM05FXR	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[39]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Triamcinolone caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[25]
Denosumab	DMNI0KO	Moderate	Additive immunosuppressive effects by the combination of Triamcinolone and Denosumab.	Low bone mass disorder [FB83]	[40]
Ceritinib	DMB920Z	Major	Decreased metabolism of Triamcinolone caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[14]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Triamcinolone caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[41]
Idelalisib	DM602WT	Major	Decreased metabolism of Triamcinolone caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[14]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Triamcinolone caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[42]
Nivolumab	DMAB9QE	Moderate	Additive immunosuppressive effects by the combination of Triamcinolone and Nivolumab.	Melanoma [2C30]	[14]
Pembrolizumab	DMFQEA6	Moderate	Additive immunosuppressive effects by the combination of Triamcinolone and Pembrolizumab.	Melanoma [2C30]	[14]
Ipilimumab	DMJTIYK	Moderate	Additive immunosuppressive effects by the combination of Triamcinolone and Ipilimumab.	Melanoma [2C30]	[14]
Cemiplimab	DMKMJHE	Moderate	Additive immunosuppressive effects by the combination of Triamcinolone and Cemiplimab.	Melanoma [2C30]	[14]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Triamcinolone caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[16]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of Triamcinolone and Thalidomide.	Multiple myeloma [2A83]	[43]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Triamcinolone and Tecfidera.	Multiple sclerosis [8A40]	[44]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Triamcinolone and Siponimod.	Multiple sclerosis [8A40]	[15]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Triamcinolone and Fingolimod.	Multiple sclerosis [8A40]	[45]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Triamcinolone and Ocrelizumab.	Multiple sclerosis [8A40]	[46]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Triamcinolone and Ozanimod.	Multiple sclerosis [8A40]	[16]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Triamcinolone caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[14]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Triamcinolone caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[47]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Triamcinolone and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[48]
Modafinil	DMYILBE	Minor	Increased metabolism of Triamcinolone caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[49]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Triamcinolone and Bupropion.	Nicotine use disorder [6C4A]	[50]
Atezolizumab	DMMF8U0	Moderate	Additive immunosuppressive effects by the combination of Triamcinolone and Atezolizumab.	Non-small cell lung cancer [2C25]	[14]
Naproxen	DMZ5RGV	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Naproxen.	Osteoarthritis [FA00-FA05]	[20]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Triamcinolone caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[51]
Aspirin	DM672AH	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Aspirin.	Pain [MG30-MG3Z]	[52]
Etodolac	DM6WJO9	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Etodolac.	Pain [MG30-MG3Z]	[20]
Diflunisal	DM7EN8I	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Diflunisal.	Pain [MG30-MG3Z]	[20]
Ibuprofen	DM8VCBE	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Ibuprofen.	Pain [MG30-MG3Z]	[20]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Triamcinolone caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[53]
Choline salicylate	DM8P137	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[54]
Bromfenac	DMKB79O	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Bromfenac.	Postoperative inflammation [1A00-CA43]	[20]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Triamcinolone caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[14]
Ritodrine	DM4V6RL	Minor	Increased risk of hypokalemia by the combination of Triamcinolone and Ritodrine.	Preterm labour/delivery [JB00]	[14]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Triamcinolone and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[55]
Gatifloxacin	DMSL679	Major	Increased risk of tendinitis/tendon rupture by the combination of Triamcinolone and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[17]
Salsalate	DM13P4C	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Salsalate.	Rheumatoid arthritis [FA20]	[54]
Meloxicam	DM2AR7L	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Meloxicam.	Rheumatoid arthritis [FA20]	[20]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Triamcinolone and Canakinumab.	Rheumatoid arthritis [FA20]	[56]
Oxaprozin	DM9UB0P	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Oxaprozin.	Rheumatoid arthritis [FA20]	[20]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Triamcinolone and Rilonacept.	Rheumatoid arthritis [FA20]	[56]
Flurbiprofen	DMGN4BY	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Flurbiprofen.	Rheumatoid arthritis [FA20]	[20]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Triamcinolone and Golimumab.	Rheumatoid arthritis [FA20]	[57]
Leflunomide	DMR8ONJ	Major	Additive immunosuppressive effects by the combination of Triamcinolone and Leflunomide.	Rheumatoid arthritis [FA20]	[38]
Salicyclic acid	DM2F8XZ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Salicyclic acid.	Seborrhoeic dermatitis [EA81]	[52]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Triamcinolone when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[58]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Triamcinolone caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[14]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Triamcinolone caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[16]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Triamcinolone caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[15]
Armodafinil	DMGB035	Minor	Increased metabolism of Triamcinolone caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[49]
LEE011	DMMX75K	Moderate	Decreased metabolism of Triamcinolone caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[59]
Pitolisant	DM8RFNJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Pitolisant.	Somnolence [MG42]	[16]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Triamcinolone caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[60]
Pipecuronium	DM5F84A	Moderate	Additive neuromuscular blocking effects by the combination of Triamcinolone and Pipecuronium.	Tonus and reflex abnormality [MB47]	[14]
Doxacurium	DMKE7L9	Moderate	Additive neuromuscular blocking effects by the combination of Triamcinolone and Doxacurium.	Tonus and reflex abnormality [MB47]	[14]
Vecuronium	DMP0UK2	Moderate	Additive neuromuscular blocking effects by the combination of Triamcinolone and Vecuronium.	Tonus and reflex abnormality [MB47]	[14]
Rocuronium	DMY9BMK	Moderate	Additive neuromuscular blocking effects by the combination of Triamcinolone and Rocuronium.	Tonus and reflex abnormality [MB47]	[14]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Triamcinolone and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[55]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Triamcinolone and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[55]
Durvalumab	DM4PVDY	Moderate	Additive immunosuppressive effects by the combination of Triamcinolone and Durvalumab.	Ureteral cancer [2C92]	[14]
Cinoxacin	DM4EWNS	Major	Increased risk of tendinitis/tendon rupture by the combination of Triamcinolone and Cinoxacin.	Urinary tract infection [GC08]	[17]
Nalidixic acid	DMRM0JV	Major	Increased risk of tendinitis/tendon rupture by the combination of Triamcinolone and Nalidixic acid.	Urinary tract infection [GC08]	[17]
-----------


⏷ Show the Full List of 131 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Benzyl alcohol	E00010	244	Antimicrobial preservative; Solvent
Hydrochloric acid	E00015	313	Acidulant
Benzalkonium chloride	E00536	21988052	Antimicrobial preservative; Penetration agent; Solubilizing agent; Surfactant
Carboxymethylcellulose sodium	E00621	Not Available	Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Dextrose anhydrous	E00394	107526	Binding agent; Diluent; Flavoring agent; Tonicity agent
Edetate disodium	E00186	8759	Complexing agent
Nitrogen	E00033	947	Aerosol propellant; Sparging agent
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Sodium chloride	E00077	5234	Diluent; Tonicity agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Water	E00035	962	Solvent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
--------------------


⏷ Show the Full List of 12 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Triamcinolone 55ug spray	55ug	Spray	Nasal
Triamcinolone 40mg/ml suspension	40mg/ml	Suspension	Intramuscular; Intraarticular
Triamcinolone 0.05% ointment	0.05%	Ointment	Topical

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Triamcinolone FDA Label
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Oral bioavailability of triamcinolone tablets and a triamcinolone diacetate suspension. Pharm Res. 1990 May;7(5):558-60. doi: 10.1023/a:1015889305157.
4	BDDCS applied to over 900 drugs
5	FLORINI JR, SMITH LL, BUYSKE DA: Metabolic fate of a synthetic corticosteroid (triamcinolone) in the dog. J Biol Chem. 1961 Apr;236:1038-42.
6	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8	Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents. Leuk Res. 2010 Jul;34(7):917-24. doi: 10.1016/j.leukres.2009.12.002. Epub 2010 Feb 8.
9	Apoptosis of airway epithelial cells induced by corticosteroids. Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1939-47. doi: 10.1164/ajrccm.164.10.2103013.
10	Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol. 2004 Sep;151(3):397-406. doi: 10.1530/eje.0.1510397.
11	Steroid myopathy induced by epidural triamcinolone injection. Br J Rheumatol. 1995 Apr;34(4):385-6. doi: 10.1093/rheumatology/34.4.385.
12	Albin H, Vincon G, Demotes-Mainard F, et al "Effect of aluminium phosphate on the bioavailability of cimetidine and prednisolone." Eur J Clin Pharmacol 26 (1984): 271-3. [PMID: 6723769]
13	Brooks SM, Werk EE, Ackerman SJ, Sullivan I, Thrasher K "Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma." N Engl J Med 286 (1972): 1125-8. [PMID: 4553339]
14	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
15	Cerner Multum, Inc. "Australian Product Information.".
16	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
17	FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
18	Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
19	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
20	Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
21	Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
22	Cerner Multum, Inc. "Canadian Product Information.".
23	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
24	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
25	Bartoszek M, Brenner AM, Szefler SJ "Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy." Clin Pharmacol Ther 42 (1987): 424-32. [PMID: 3665340]
26	Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
27	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
28	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
29	Frey BM, Frey FJ "Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans." Eur J Clin Invest 14 (1984): 1-6. [PMID: 6230241]
30	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
31	Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease." Clin Pharmacokinet 43 (2004): 803-21. [PMID: 15355126]
32	Chrousos GA, Kattah JC, Beck RW, Cleary PA "Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial." JAMA 269 (1993): 2110-2. [PMID: 8468765]
33	Kyriazopoulou V, Parparousi O, Vagenakis AG "Rifampicin-induced adrenal crisis in Addisonian patients receiving corticosteroid replacement therapy." J Clin Endocrinol Metab 59 (1984): 1204-6. [PMID: 6490796]
34	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
35	Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
36	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
37	Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
38	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
39	Messer J, Reitman D, Sacks HS, et al "Association of adrenocorticosteroid therapy and peptic-ulcer disease." N Engl J Med 309 (1983): 21-4. [PMID: 6343871]
40	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
41	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
42	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
43	Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
44	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
45	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
46	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
47	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
48	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
49	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
50	Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
51	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
52	Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD "Risk of adverse gastrointestinal events from inhaled corticosteroids." Pharmacotherapy 28 (2008): 1325-34. [PMID: 18956992]
53	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
54	Baer PA, Shore A, Ikeman RL "Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis." Arthritis Rheum 30 (1987): 345-7. [PMID: 3566826]
55	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
56	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
57	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
58	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
59	DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
60	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.